These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 35183167)

  • 61. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.
    Laorden D; Hernández I; Domínguez-Ortega J; Romero D; Álvarez-Sala R; Quirce S
    Eur Ann Allergy Clin Immunol; 2024 Jul; 56(4):169-175. PubMed ID: 36927725
    [No Abstract]   [Full Text] [Related]  

  • 63. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years.
    Korn S; Bourdin A; Chupp G; Cosio BG; Arbetter D; Shah M; Gil EG
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4381-4392.e4. PubMed ID: 34487870
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
    Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
    Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
    J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
    Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
    [No Abstract]   [Full Text] [Related]  

  • 69. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
    Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
    BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study.
    Campisi R; Nolasco S; Pelaia C; Impellizzeri P; D'Amato M; Portacci A; Ricciardi L; Scioscia G; Crimi N; Scichilone N; Foschino Barbaro MP; Pelaia G; Carpagnano GE; Vatrella A; Crimi C;
    J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373648
    [No Abstract]   [Full Text] [Related]  

  • 71. One year of mepolizumab. Efficacy and safety in real-life in Italy.
    Bagnasco D; Caminati M; Menzella F; Milanese M; Rolla G; Lombardi C; Bucca C; Heffler E; Paoletti G; Testino E; Manfredi A; Caruso C; Guida G; Senna G; Bonavia M; Riccio AM; Canonica GW; Passalacqua G
    Pulm Pharmacol Ther; 2019 Oct; 58():101836. PubMed ID: 31473366
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach.
    Genofre E; Carstens D; DeBacker W; Muchmore P; Panettieri RA; Rhodes K; Shih VH; Trudo F
    Respir Res; 2023 May; 24(1):121. PubMed ID: 37131265
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.
    Chupp G; Lugogo NL; Kline JN; Ferguson GT; Hirsch I; Goldman M; Zangrilli JG; Trudo F
    Ann Allergy Asthma Immunol; 2019 May; 122(5):478-485. PubMed ID: 30802500
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
    Pham DN
    J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study).
    Wedner HJ; Fujisawa T; Guilbert TW; Ikeda M; Mehta V; Tam JS; Lukka PB; Asimus S; Durżyński T; Johnston J; White WI; Shah M; Werkström V; Jison ML;
    Pediatr Allergy Immunol; 2024 Mar; 35(3):e14092. PubMed ID: 38491795
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 78. Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series.
    Menzella F; Bonavia M; Bonini M; D'Amato M; Lombardo S; Murgia N; Patella V; Triggiani M; Pelaia G
    J Asthma Allergy; 2021; 14():149-161. PubMed ID: 33654412
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
    Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
    Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.